Biomarker imprecision in precision medicine

  title={Biomarker imprecision in precision medicine},
  author={Kenneth P.H. Pritzker},
  journal={Expert Review of Molecular Diagnostics},
  pages={685 - 687}
  • K. Pritzker
  • Published 2018
  • Medicine
  • Expert Review of Molecular Diagnostics
Precision medicine is a conceptual model for disease taxonomy, formally devised in 2011, that extends the long-established clinical pathologic correlation disease model to include and emphasize genetics, genomics, and systems biology knowledge [1]. Precision medicine has the goal to provide more effective therapy for individuals guided by more precise diagnostics. This includes imaging, molecular diagnostics, and other ‘omics’ data as well as the analysis of large data sets by advanced… Expand
5 Citations

Topics from this paper

Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application
This review highlights the current progress on the development of biomarkers, describing the proteomics technologies used, the most promising findings and the challenges encountered. Expand
Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application.
Two new biomarker discovery studies have praised the value of their emerging results, predicting an unprecedented impact on health care and the need for further research into these technologies. Expand
Core needle biopsy wash as a tool for acquiring additional diagnostic material for laboratory testing
The core needle biopsy wash is an under-recognised and underutilised approach to extending the diagnostic capabilities of the limited amount of targeted material obtained during this common procedure. Expand
Nonlinear Ultrasound Converts a Medical Needle into a Precision Medicine Instrument
The SonoLancet enhances adequacy of tissue biopsy for many precision medicine applications including molecular diagnostics and has the potential to advance several other applications relevant to precision medicine, including drug or gene delivery, cell modulation, and minimally invasive surgical procedures. Expand
On-chip integrated optical stretching and electrorotation enabling single-cell biophysical analysis
A team led by Wenhui Wang from Tsinghua University report a microfluidic chip that enables simultaneous probing of the mechanical and electrical behavior of single cells and shows the potential of the chip in cancer research. Expand


Bioinformatics advances for clinical biomarker development.
The key message is that more effective biomarker development requires database input of higher quality, improved bioinformatics tools to identify more clearly the acceptable criteria for each development step, as well as more and better database linkages. Expand
Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer1
It is posited that mathematical models can improve the application of anticancer therapeutics in the era of precision medicine and is compared to chemotherapy to radiation therapy. Expand
Significance of Pharmacogenomics in Precision Medicine
  • I. Cascorbi
  • Medicine
  • Clinical pharmacology and therapeutics
  • 2018
This issue of Clinical Pharmacology & Therapeutics on the significance of pharmacogenomics in precision medicine discusses the ongoing challenges on different levels. Expand
Precision medicine--delivering the goods?
The state-of-the-art in precision medicine from hematological malignancies and solid tumors with the current gold standard diagnostic and therapy to basic and translational research utilizing nanotechnology and RNA interference strategies for future personalized theranostics in oncology is summarized. Expand
Building the foundation for genomics in precision medicine
To accelerate the adoption of precision medicine, fundamental changes are needed in the infrastructure and mechanisms for data collection, storage and sharing to create a continuously learning health-care system with seamless cycling between clinical care and research. Expand
Cancer biomarkers: easier said than done.
With the above enablers, novel cancer biomarkers may be useful, both for assessing early and established neoplasia more precisely and for contributing data toward development of novel practical concepts regarding cancer biology. Expand
Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine
This review focuses on lessons learned through early attempts of clinically implementingPGx testing; the challenges and opportunities that PGx testing brings to precision medicine in the era of NGS. Expand
Delivering on the value proposition of precision medicine: the view from healthcare payers.
A long-held assumption and expectation has been that genomics-based precision medicine will provide clinicians with the tools and therapies they need to consistently deliver the right treatment toExpand
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
The immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer and supports the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer. Expand
The paradox of precision medicine
How approaches to precision medicine can lead, paradoxically, to increased levels of uncertainty is described and recommendations for how physicians can better navigate new uncertainties in precision medicine are offered. Expand